0001742496-26-000005.txt : 20260601 0001742496-26-000005.hdr.sgml : 20260601 20260601200012 ACCESSION NUMBER: 0001742496-26-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260528 FILED AS OF DATE: 20260601 DATE AS OF CHANGE: 20260601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moss Gregory S. CENTRAL INDEX KEY: 0001742496 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42938 FILM NUMBER: 261053194 MAIL ADDRESS: STREET 1: 450 EAST 29TH STREET, 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evommune, Inc. CENTRAL INDEX KEY: 0002044725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 850742575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1891 PAGE MILL RD CITY: PALO ALTO STATE: CA BUSINESS PHONE: (650) 223-7745 MAIL ADDRESS: STREET 1: 1891 PAGE MILL RD CITY: PALO ALTO STATE: CA 4 1 primarydocument.xml PRIMARY DOCUMENT X0609 4 2026-05-28 false 0002044725 Evommune, Inc. EVMN 0001742496 Moss Gregory S. false C/O EVOMMUNE, INC. 1891 PAGE MILL ROAD PALO ALTO CA 94304 false true false false Chief Business & Legal Officer true Common Stock 2026-05-28 4 M false 14223.00 1.71 A 75058.00 D Common Stock 2026-05-28 4 S false 14223.00 22.83 D 60835.00 D Common Stock 3175.00 I By Trust Employee Stock Option (Right to Buy) 1.71 2026-05-28 4 M false 14223.00 0.00 D 2034-03-21 Common Stock 14223.00 47845.00 D The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. /s/ Gregory S. Moss 2026-06-01